A clinically useful approach to enhance immunological memory and antitumor immunity.
Persistence of vaccine-induced immune responses, not the initial magnitude, best correlates with protective antitumor immunity. In mice, oligonucleotide aptamer-targeted siRNA inhibition of mammalian target of rapamycin (mTOR) activity in activated CD8+ T cells promotes their differentiation into functionally competent memory cells leading to enhanced antitumor immunity, a protective effect superior to that of non-targeted administration of the mTOR inhibitor rapamycin.
['Berezhnoy|Alex|A|', 'Rajagopalan|Anugraha|A|', 'Gilboa|Eli|E|']
mTOR 4-1BB costimulation T cell memory Tumor immunity aptamers